Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Noa Biran, MD, John Theurer Cancer Center
Q&As
Step-Up Dosing for Multiple Myeloma Treatment in the Outpatient Setting
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the...
05/06/2024
Oncology
Noa Biran, MD, Hackensack Meridian Health
Conference Coverage
Evaluating Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a...
05/06/2024
Oncology
Gareth Morgan, MD, NYU Langone Medical Center
Conference Coverage
Assessing the Strength of Minimal Residual Disease Testing for Patients With Multiple Myeloma
04/19/2024

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in...
04/19/2024
Oncology
David Siegel, MD, PhD, Hackensack Meridian Health
Conference Coverage
Exploring the Role of Stem Cell Transplant for Patients With Myeloma Older Than 65
04/19/2024

Featuring David Siegel, MD, PhD

Featuring David Siegel, MD, PhD ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates &...
04/19/2024
Oncology
Brea Lipe, University of Rochester Medical Center
Conference Coverage
Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?
04/16/2024

Featuring Brea Lipe, MD

Featuring Brea Lipe, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, MEd, FRCPC, FACP
Conference Coverage
Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?
04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates &...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment
04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates &...
04/09/2024
Lymphoma, Leukemia & Myeloma Network
Ashley Rosko, MD
Conference Coverage
Analyzing Comprehensive Health of Patients With Multiple Myeloma for Transplant Decision-Making
04/08/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Ashley Rosko, MD, discusses why the comprehensive health of patients with multiple myeloma should be analyzed to make transplant decisions, rather than only focusing on...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Ashley Rosko, MD, discusses why the comprehensive health of patients with multiple myeloma should be analyzed to make transplant decisions, rather than only focusing on...
At the 2024 Great Debates &...
04/08/2024
Oncology
Andrew Yee, MD
Conference Coverage
Should Additional BCMA Therapy be Utilized After Previous BCMA Therapy?
04/08/2024

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses whether or not it is suitable for a patient to receive additional BCMA therapy after previous BCMA therapy.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses whether or not it is suitable for a patient to receive additional BCMA therapy after previous BCMA therapy.
At the 2024 Great Debates &...
04/08/2024
Oncology

Advertisement

Advertisement

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement